JAPMA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Porthouse, J.
Right arrow Articles by Torgerson, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Porthouse, J.
Right arrow Articles by Torgerson, D. J.
Journal of the American Podiatric Medical Association
Volume 94 Number 3 221-228 2004
Copyright © 2004 American Podiatric Medical Association

PODIATRIC RESEARCH FROM THE UNITED KINGDOM

The Need for Randomized Controlled Trials in Podiatric Medical Research

Jill Porthouse, MSc * and David J. Torgerson, PhD *

* York Trials Unit, Department of Health Sciences, University of York, York, England.

Corresponding author: Jill Porthouse, MSc, York Trials Unit, Department of Health Sciences, University of York, York YO10 5DD, England.

Abstract

The randomized controlled trial is the most robust method available to evaluate health-care treatments. If podiatric medical practice is to be based on rigorous evidence, then high-quality randomized controlled trials are needed to inform that practice. In this article, we examine the extent to which randomized controlled trials are used in recent podiatric medical research and appraise the quality of those that are available. Using the Cochrane database of all randomized controlled trials in health care, we found only six relevant trials undertaken in podiatric medicine since 1997. These studies were of variable quality. We also discuss the key features of a rigorous trial design. To date, the clinical practice of podiatric medicine is not adequately informed by the best available evidence. We call for more high-quality randomized controlled trials to be undertaken in podiatric medical research. (J Am Podiatr Med Assoc 94(3): 221–228, 2004)




This article has been cited by other articles:


Home page
 J. Am. Podiatr. Med. Assoc.Home page
N. Frescos and H. B. Menz
Foot Health Service Provision by the Australian Department of Veterans' Affairs: Do Major Podiatric Medical Interventions Reduce the Number of Maintenance Treatments?
J Am Podiatr Med Assoc, November 1, 2007; 97(6): 469 - 474.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Podiatr. Med. Assoc.Home page
A. Martinez-Nova, R. Sanchez-Rodriguez, and D. Alonso-Pena
A New Onychocryptosis Classification and Treatment Plan
J Am Podiatr Med Assoc, September 1, 2007; 97(5): 389 - 393.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Podiatr. Med. Assoc.Home page
K. B. Landorf
Letter to the editor: cimetidine as a first-line therapy for pedal verruca.
J Am Podiatr Med Assoc, March 1, 2006; 96(2): 184 - 185.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Podiatric Medical Association.